Form 8-K - Current report:
SEC Accession No. 0001193125-22-245613
Filing Date
2022-09-15
Accepted
2022-09-15 16:06:54
Documents
14
Period of Report
2022-09-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d369438d8k.htm   iXBRL 8-K 46029
2 EX-99.1 d369438dex991.htm EX-99.1 85700
3 EX-99.2 d369438dex992.htm EX-99.2 19453
  Complete submission text file 0001193125-22-245613.txt   309193

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA syrs-20220915.xsd EX-101.SCH 2852
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20220915_lab.xml EX-101.LAB 17996
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20220915_pre.xml EX-101.PRE 11259
8 EXTRACTED XBRL INSTANCE DOCUMENT d369438d8k_htm.xml XML 3359
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 221245864
SIC: 2834 Pharmaceutical Preparations